Researcher
Peter Van Dam
- Research Expertise:Translational investigations in breat and cervical cancer Immune environment in inflammatory breast cancer and cervical cancer Effect of Denosumab on the immune environment of cervical cancer Quality control of cancer treatment Telemonitoring of sidde effects of cancer treatment Cognitive impairment after cancer treatment
- Keywords:T CYTOTOXIC LYMPHOCYTE, T HELPER LYMPHOCYTE, Medicine
- Disciplines:Cancer biology, Cancer diagnosis, Cancer therapy
- Research techniques:Immunohistochemical staining Flow cytometry RNA seq
- Users of research expertise:Other interested groups
Affiliations
- Center for Oncological Research (CORE) (Research group)
Member
From1 Jan 2019 → Today - Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO) (Research group)
Member
From1 Feb 2014 → 31 Dec 2018
Projects
1 - 9 of 9
- Reinvigorating the antitumor immunity in human breastand cervical cancer with an innovative RANK(L) targeted combination strategy.From1 Nov 2021 → TodayFunding: Nonprofit institution or equivalents
- Development and validation of a novel rationally designed immunotherapeutic combination strategy built upon targeting RANK(L) for cervical cancer.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Acquired immunity and immunologic aspects of SARS-CoV-2 infection a population of patients and healthcare workers in Multidisciplinary Oncologic Centres. (MOCOR-Study).From1 Jun 2020 → 31 May 2021Funding: BOF - projects
- Unveiling the drug repurposing versatility of denosumab in the battle against human cervical cancer.From1 Jan 2020 → 31 Dec 2020Funding: Nonprofit institution or equivalents
- Integrated Personalized & Precision Oncology Network (IPPON).From1 Jan 2020 → TodayFunding: BOF - research organisations, Fund Recuperation Fiscal Exemption
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2018 → 30 Sep 2020Funding: FWO fellowships
- RANK signaling and checkpoint inhibition.From15 Sep 2018 → 14 Sep 2021Funding: Nonprofit institution or equivalents
- The role of infiltrating immune cells in the aggresive phenotype of inflammatory breast cancer and possible new (immuno)therapeutic targets.From1 Oct 2016 → 30 Sep 2018Funding: FWO fellowships
- Characterization of the stromal component in inflammatory breast cancer.From15 Jan 2016 → 14 Jan 2017Funding: Nonprofit institution or equivalents
Publications
31 - 40 of 107
- Blood cytokine analysis suggests that SARS-CoV-2 infection results in a sustained tumour promoting environment in cancer patients(2021)
Authors: Fien De Winter, An Hotterbeekx, Manon Huizing, Angelina Konnova, Erik Fransen, Bart 's Jongers, Ravi Kumar Jairam, Vincent Van Averbeke, Pieter Moons, Ella Roelant, et al.
Pages: 1 - 19 - Meeting the challenges in cancer care management during the SARS-Cov-2 pandemic(2021)
Authors: Marika Rasschaert, Pieterjan Vanclooster, Laura Depauw, Tim Mertens, Ella Roelant, Elke Coenen, Sébastien Anguille, Annelies J R Janssens, Peter Van Dam, Marc Peeters
- The non-bone-related role of RANK/RANKL signaling in cancer(2020)
Authors: Peter Van Dam, Yannick Verhoeven, Xuan Bich Trinh
Pages: 53 - 62 - A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer(2020)
Authors: Christophe Van Berckelaer, M. Van Geyt, S. Linders, Charlotte Rypens, Xuan Bich Trinh, Wiebren Tjalma, Steven Van Laere, Cecile Colpaert, Luc Dirix, Peter Van Dam
Pages: 212 - 220 - Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer(2020)
Authors: Simone N. Koole, Leigh Bruijs, Cristina Fabris, Karolina Sikorska, Maurits Engbersen, Jules H. Schagen van Leeuwen, Henk W.R. Schreuder, Ralph H. Hermans, Jacobus van der Velden, Henriette J.G. Arts, et al.
Pages: 1928 - 1934 - AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients(2020)
Authors: Marika Rasschaert, Christof Vulsteke, Sven De Keersmaeker, Kathleen Vandenborne, Stefanie Dias, Vincent Verschaeve, Peter Vuylsteke, Ilse Van Brussel, Jo Ravelingien, Peter Van Dam, et al.
Pages: 1 - 9 - Acceptability of quality indicators for the management of endometrial, cervical and ovarian cancer: results of an online survey(2020)
Authors: Annemie Luyckx, Leen Wyckmans, Anne-Sophie Bonte, Xuan Bich Trinh, Peter Van Dam
- Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity(2020)
Authors: Charlotte Rypens, Melike Marsan, Christophe Van Berckelaer, Kirsten Melis, Sara Perez Lopez, Peter Van Dam, Gayathri R. Devi, Pascal Finetti, Naoto T. Ueno, François Bertucci, et al.
Pages: 385 - 395 - HIPEC in advanced epithelial ovarian cancer(2020)
Authors: Jan Vermorken, Peter Van Dam, Alison Brand
Pages: 451 - 458 - Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform(2020)
Authors: Marc Peeters, Peter Van Dam, Marika Anna Rasschaert, Christof Vulsteke, Lieselot Croes, Ilse Van Brussel, Jo Ravelingien, Hans Prenen
Pages: 1 - 3